References
Oral loratadine in the management of G-CSF-induced bone pain: a pilot study
Abstract
This pilot study aimed to ascertain if bone pain induced by granulocyte-colony stimulating factors (G-CSFs) can be alleviated or eliminated by oral antihistamine loratadine. Twelve patients with cancer receiving chemotherapy were included in the study. Daily pain increased between before treatment started and after cycle 1 in all patients. All 12 participants were started on loratadine on cycle 2; three patients were taking pain medications in addition to this as needed, which were ibruprofen (
Pegfilgrastim (Neulasta) is a recombinant human granulocyte-colony stimulating factor (G-CSF) agent used for primary or secondary prophylaxis of febr ile neutropenia in patients receiving myelosuppressive chemotherapy. It is administered as a single 6 mg subcutaneous injection 24–72 hours after completion of a chemotherapy cycle. Pain is a common side effect and, although G-CSF-associated bone pain is usually mild to moderate, severe pain can occur (Gregory et al, 2010; Bondarenko et al, 2016; Xu et al, 2016). The exact mechanisms of bone pain related to G-CSF have yet to be elucidated, but a younger age and a history of bone pain have been identified as risk factors (Xu et al, 2016). In addition, it is reported that administering G-CSF at 14:00 (as opposed to 10:00) results in significantly less pain for patients (Özkaraman et al, 2017).
Register now to continue reading
Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to clinical or professional articles
-
Unlimited access to the latest news, blogs and video content